CRISPR Therapeutics AG Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2015 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
CRISPR Therapeutics AG quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2015 to Q4 2023.
- CRISPR Therapeutics AG Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $133M, a 12.6% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)